ArriVent BioPharma, Inc. (AVBP) Stock Price & Analysis
ArriVent BioPharma, Inc. (AVBP) is trading at USD 10.7, up 0.09% today, as of November 18, 2026 at 17:02 UTC (US market open; quotes may be delayed), according to Nexqual market data.
AVBP last closed at USD 10.69; today's session has ranged USD 10.33–11.11 on volume of 174,725 shares. Market capitalization is $553.44M, with a 52-week range of USD 10.33–35.83 (NGM). Source: Nexqual, retrieved November 18, 2026 at 17:03 UTC.
What changed for AVBP since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- ArriVent BioPharma, Inc. (AVBP) stock went from USD 19.12 (close of the week of Aug 25, 2025, split-adjusted) to USD 10.7, a -44.0% price change; the S&P 500 (SPY) moved +14.7% over the same period.
- Analyst actions on AVBP in the last 120 days: 12 (3 upgrades or target raises, 8 downgrades or target cuts); most recent Truist Securities, Nov 10, 2026.
Also available as compact Markdown for AI agents: nexqual.com/AVBP.md
Key facts (AVBP)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 26.2 (range 22–29).
- Total return with dividends: 1Y -47.1% vs S&P 500 +11.8%; 5Y -46.5% vs S&P 500 +66.4%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: AVBP paid no cash dividend in the last five years.
- Short interest: 11.98% of float (as of 2026-10-30), 2.4 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AVBP)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$74.6M | -$94.3M | -$178M | -$181M |
| Net income | -$69.3M | -$80.5M | -$166M | -$169M |
| EPS (diluted) | -$32.38 | -$2.56 | -$4.32 | — |
| Cash + short-term investments | $150M | $219M | $313M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (AVBP)
P/B 1.4x · Earnings yield -30.55%
Analysts (AVBP)
Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 26.2 (low 22, high 29).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-10 | Truist Securities | Target raised | Buy | $21 → $24 |
| 2026-10-27 | Guggenheim | Target raised | Buy | $18 → $30 |
| 2026-10-20 | B. Riley Securities | Target lowered | Buy | $45 → $29 |
| 2026-10-16 | BTIG | Reiterated | Buy | $29 |
| 2026-10-08 | HC Wainwright & Co. | Target lowered | Buy | $47 → $27 |
| 2026-10-07 | Citigroup | Target lowered | Buy | $40 → $20 |
| 2026-10-07 | Jones Trading | Target lowered | Buy | $45 → $22 |
| 2026-10-07 | Truist Securities | Target lowered | Buy | $45 → $18 |
| 2026-10-07 | Guggenheim | Target lowered | Buy | $45 → $18 |
| 2026-10-07 | BTIG | Target lowered | Buy | $42 → $29 |
| 2026-08-17 | HC Wainwright & Co. | Target raised | Buy | $44 → $47 |
| 2026-08-13 | Citigroup | Target lowered | Buy | $43 → $40 |
Total return (dividends reinvested) (AVBP)
| 1Y (from 2025-11-18) | 5Y (from 2024-01-22) | |
|---|---|---|
| Total return | -47.1% | -46.5% |
| S&P 500 (SPY) | +11.8% | +66.4% |
| Per year | -47.1% | -19.9% |
| Volatility (annualized) | 94.0% | 65.3% |
| Max drawdown | -69.2% (Jun 2026→Nov 2026) | -69.2% (Jun 2026→Nov 2026) |
Dividends (AVBP)
AVBP paid no cash dividend in the last five years.
Short interest (AVBP)
5,797,018 shares sold short, 11.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 8,451,472 shares (-31.4%). Days to cover: 2.4 (short shares ÷ average daily volume).
AVBP major shareholder filing: Schedule 13D/A, Oct 8, 2026
ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P. filed a Schedule 13D/A with the SEC on Oct 8, 2026, reporting up to 5.80% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …
Source: SEC EDGAR, Schedule 13D/A filed Oct 8, 2026. Quoted word for word; Nexqual adds no interpretation.
AVBP earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 9, 2026 | Quarter ended Sep 30, 2026 | −$0.81 | −$1.06 | Beat +23.6% | -1.1% |
| Aug 12, 2026 | — | — | — | — | -4.4% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.96 | −$0.89 | Miss −7.9% | -1.8% |
| Mar 5, 2026 | — | — | — | — | -11.8% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$0.83 | −$0.78 | Miss −6.4% | +7.4% |
| Aug 11, 2025 | — | — | — | — | -5.8% |
| May 12, 2025 | — | — | — | — | -5.2% |
| Mar 3, 2025 | — | — | — | — | -7.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
AVBP recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 9, 2026 | 8-K | Quarterly results; Director or executive officer change, or pay arrangement “On November 6, 2026, Stuart Lutzker, M.D., Ph.D. notified the Company of his intention to retire from the position of President, Research and Development of the Company and as a director of the Company, effective as of December 1, 2026 (the "Retirement Date"). Dr. Lutzker's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. In connection with Dr. Lutzker's retirement from the Company, the Company intends to enter into a…” |
| Nov 5, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 5.8% of shares, passive 5%+ holder (amended) |
| Oct 26, 2026 | 8-K | Regulation FD disclosure; Other material event |
| Oct 19, 2026 | 8-K | Regulation FD disclosure |
| Oct 13, 2026 | Schedule 13G | Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P.: 5.0% of shares, passive 5%+ holder |
| Oct 13, 2026 | 8-K | Regulation FD disclosure; Other material event |
| Oct 8, 2026 | Schedule 13D/A | ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC: 5.8% of shares, 5%+ holder that may seek to influence the company (amended) “The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from…” |
| Oct 6, 2026 | 8-K | Regulation FD disclosure; Other material event |
| Aug 12, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 12, 2026 | 8-K | Entered a material agreement; Quarterly results “On August 11, 2026, ArriVent BioPharma, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Allist License Agreement") with Shanghai Allist Pharmaceuticals Co., Ltd. ("Allist"), a pharmaceutical company incorporated under the laws of China. Pursuant to the Allist License Agreement, the Company granted Allist an exclusive, sublicensable (through multiple tiers), royalty-bearing license under certain intellectual property owned or controlled by the Company to research, develop, manufacture,…” |
| Jul 27, 2026 | Schedule 13G/A | passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
AVBP suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | WuXi | “Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture …” |
| Supplier | SynTheAll Pharmaceutical | “Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture …” |
| Supplier | Fortrea Holdings Inc. (FTRE) | “Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.” |
| Supplier | Icon Clinical Research | “Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.” |
| Supplier | Syneos Health | “Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.” |
| Partner | Shanghai Allist Pharmaceuticals | “The parties have appointed a joint collaboration committee, comprised of representatives from both us and Allist (the Collaboration Committee), to oversee the parties' development activities related to the Licensed Compound under the Allist License Agreement.” |
| Partner | Aarvik Therapeutics | “Also in 2021, we entered into a research collaboration, as amended, with Aarvik Therapeutics, Inc. (Aarvik) to leverage its proprietary multi-target, multivalent, site-specific conjugation antibody platform to discover next-generation antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs.” |
| Partner | Lepu Biopharma | “In January 2025, we entered into an Exclusive License Agreement (the Lepu Biopharma Agreement) with Lepu Biopharma Co. Ltd. (Lepu Biopharma) pursuant to which Lepu Biopharma granted us the right to develop and commercialize ARR-217 (MRG007), a CD-H17-targeting ADC for gastrointestinal cancers outside greater China, which includes mainland China, Hong Kong, Macau, and Taiwan.” |
| Partner | Jiangsu Alphamab Biopharmaceuticals | “Our Alphamab Antibody Drug Conjugate Collaboration” |
| Competitor | Johnson & Johnson (JNJ) | “Companies that compete with us directly on the level of commercialization or development of product candidates targeting EGFR mutation-positive NSCLC include, but are not limited to, AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Inc., Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim and Bayer AG.” |
Quoted from the company's 10-K filed Mar 5, 2026.
AVBP company outlook (results filed Nov 9, 2026)
- “Cash and investments of $393.2 million as of September 30, 2026 expected to fund operations to mid-2028 NEWTOWN SQUARE, PA, November 9, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc.”
- “Phase 1b dose optimization data for ARR-217 in late line colorectal cancer are expected in the first half of 2027, and ARR-217 combination data with bevacizumab as well as combination data with chemotherapy are expected in the second half of 2027. 2026 Financial Results ·”
- “As of September 30, 2026, the Company had cash and investments of $393.2 million, which is expected to fund operations to mid-2028. ·”
Quoted word-for-word from the SEC 8-K results press release.
AVBP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.99 | $-1.01 | +$0.02 | $0 | 10 |
| Next quarter (ends Dec 2026) | $-0.91 | $-0.98 | +$0.07 | $3.1M | 10 |
| Current fiscal year (ends Dec 2026) | $-3.90 | $-4.34 | +$0.44 | $5.0M | 9 |
| Next fiscal year (ends Dec 2027) | $-3.56 | $-3.81 | +$0.25 | $6.8M | 10 |
AVBP options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 237.4% | ±14.3% |
| Dec 18, 2026 | 30 | 114.3% | ±26.3% |
| Jan 15, 2027 | 58 | 104.6% | ±33.0% |
| Apr 16, 2027 | 149 | 95.0% | ±47.8% |
30-day implied volatility 122.1% vs 123.3% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 17:03 UTC)
| Price | USD 10.7 |
|---|---|
| Change | ▲ 0.09% (up) |
| Previous Close | USD 10.69 |
| Open | USD 10.42 |
| Day Range | USD 10.33 – 11.11 |
| 52-Week Range | USD 10.33 – 35.83 |
| Volume | 174,725 shares |
| Market Cap | $553.44M |
| Exchange | NGM |
Technical Analysis (AVBP)
Nexqual's technical model rates AVBP "SELL" based on 2 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 17:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.15 (oversold) |
| vs SMA50 | Below (USD 20.2) |
| MACD | -2.39 (negative) |
Analyst Ratings (AVBP)
Wall Street analysts rate AVBP "Buy" based on 11 analysts, with a mean price target of USD 26.2 (range USD 22–29), per Nexqual as of November 18, 2026 at 17:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 26.2 |
| High Target | USD 29 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (AVBP)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.99 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.81 vs est -1.06 ▲ beat |
| 2026-03-31 | USD -0.96 vs est -0.89 ▼ miss |
| 2025-09-30 | USD -0.83 vs est -0.78 ▼ miss |
Source: Nexqual, November 18, 2026 at 17:03 UTC.
Financials & Fundamentals (AVBP)
| Total Revenue | $5.00M |
|---|---|
| Gross Margin | +146.46% |
| Operating Margin | -3620.00% |
| Profit Margin | +0.00% |
| ROE | -48.67% |
| Debt / Equity | 0 |
| Current Ratio | 17.64 |
| Total Cash | $393.22M |
| Total Debt | $256,000 |
Source: Nexqual, November 18, 2026 at 17:03 UTC.
Financial Health Score (AVBP)
Nexqual rates ArriVent BioPharma, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 17:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $393M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$161M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -43%, ROA -40.5% (last 4 quarters, SEC) |
Ownership (AVBP)
| Insider Ownership | +1.47% |
|---|---|
| Institutional Ownership | +103.16% |
| Shares Outstanding | 51.72M |
| Float | 32.01M |
| Short % of Float | +11.98% |
Source: Nexqual, November 18, 2026 at 17:03 UTC.
Leadership (AVBP)
ArriVent BioPharma, Inc. is led by Zhengbin Yao, Co-Founder, Chairman, President & CEO, per Nexqual as of November 18, 2026 at 17:03 UTC.
| Co-Founder, Chairman, President & CEO | Zhengbin Yao |
|---|---|
| Co-Founder, President of Research & Development and Director | Stuart Lutzker |
| CFO & Treasurer | Winston Kung |
| Co-Founder & COO | Robin LaChapelle M.A. |
| Chief Technology Officer | Yang Wang |
Major Backers & Investors (AVBP)
Notable institutional backers of ArriVent BioPharma, Inc. include Montanova Capital LLC, Infinitum Asset Management, LLC , HHLR Advisors, LTD, according to Nexqual as of November 18, 2026 at 17:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Montanova Capital LLC | 9.52% |
| Infinitum Asset Management, LLC | 8.75% |
| HHLR Advisors, LTD | 7.6% |
| Orbimed Advisors LLC. | 5.85% |
| FMR, LLC | 5.74% |
| Fidelity | 4.57% |
| Octagon Capital Advisors LP | 4.14% |
| Vivo Capital, LLC | 3.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.59% |
| Vanguard Group | 3.89% |
Source: Nexqual, November 18, 2026 at 17:03 UTC.
From ArriVent BioPharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- EGFRm are detected by numerous commercially available FDA-approved DNA tests, either Polymerase Chain Reaction (PCR) or Next Generation Sequencing (NGS), utilizing either tumor tissue or blood samples and testing for EGFRm, as well as other activating gene mutations, is considered standard in the management of NSCLC as per national guidelines such as National Comprehensive Cancer Network (NCCN).
- We believe that our deep expertise in developing oncology drugs, executing cross border business transactions and track record building companies will allow us to expand our portfolio globally, across the oncology landscape.
Partnerships
- In 2024, we entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab), a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel ADCs for the treatment of cancers globally, with the exception of greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
Legal & Regulatory Risks (Item 1A, quoted)
- Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials or nonclinical studies could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects.
- The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.
- Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.
- Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGON | CG Oncology, Inc. | USD 81.5 | ▲ 3.24% |
| KOD | Kodiak Sciences Inc | USD 96.25 | ▼ 0.57% |
| BLTE | Belite Bio, Inc | USD 158.13 | ▲ 0.26% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.66 | ▲ 0.35% |
| IBRX | ImmunityBio, Inc. | USD 6.6 | ▲ 5.35% |
| IMVT | Immunovant, Inc. | USD 33.55 | ▲ 1.01% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 17:03 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt